OmniQ Print Logo Black.png
March 29, 2023 08:45 ET | OMNIQ Corp.
omniQ’s AI Machine Vision technology identifies patterns and enable proactive smart decisionsomniQ’s AI Homeland Security solutions are already deployed in foreign Ministry of Defense Head Quarters,...
ARC logo.png
Passive Fire Protection Market Value Predicted To Reach US$ 5,263.7 Million By 2027: Acumen Research And Consulting
April 16, 2021 11:12 ET | Acumen Research and Consulting
LOS ANGELES, April 16, 2021 (GLOBE NEWSWIRE) -- The Global Passive Fire Protection Market is expected to grow at a CAGR of around 6.8% from 2020 to 2027 and reach the market value of over US$...
Worker Safety Pro.jpg
FallSafety Launches Emergency Check-Ins to Protect Enterprise Employees
March 15, 2021 08:00 ET | Tidyware
FallSafety launches enterprise-grade emergency check-insEmergency check-ins help protect company employees during crisisWorker protection for severe weather, social dangers, and other potentially...
Bel to Present at the Q1 Virtual Investor Summit
March 11, 2021 07:15 ET | BEL FUSE INC.
JERSEY CITY, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Bel BELFB today announced that Lynn Hutkin (Director of Financial Reporting), Farouq Tuweiq (CFO), Pete Bittner (President,...
ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of AB569 in Eradicating Multi-Drug Resistant Pathogens Acinetobacter baumannii and Acinetobacter spp
March 04, 2021 08:32 ET | Arch Biopartners
TORONTO, March 04, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that one of its lead scientists, Dr. Daniel Hassett,...
Retrophin Logo.jpg
Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
September 21, 2020 08:00 ET | Retrophin, Inc.
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety...
VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®
June 16, 2019 12:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 01, 2019 08:00 ET | VBI Vaccines, Inc.
All four lead pipeline programs progressing towards expected clinical milestones in 2019Gearing up for top-line data from the pivotal Phase 3 study of Sci-B-Vac®, VBI’s trivalent hepatitis B vaccine,...
VBI Vaccines Provides Update on GBM Program and Announces Upcoming Conference Call
April 23, 2019 08:00 ET | VBI Vaccines, Inc.
10mcg dose selected to advance into Part B of Phase 1/2a study of VBI-1901 in recurrent GBMExpanded data from Part A of the Phase 1/2a study of VBI-1901 selected for poster presentation at...
VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
October 16, 2018 08:00 ET | VBI Vaccines, Inc.
Vaccination complete in 1,537 subjects in PROTECT Phase 3 studyNo vaccine-related adverse events have been observed to-dateTop-line data expected mid-2019 CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE...